BioPharma Provides $500MM Term Loan for TESARO

TESARO, an oncology-focused biopharmaceutical company, entered into a definitive term loan agreement with Biopharma Credit and BioPharma Credit Investments IV, investment funds managed by Pharmakon Advisors.

Pharmakon, Athyrium Capital Provide $150MM Debt Financing to Halozyme

Halozyme Therapeutics closed a $150 million royalty-backed debt transacton with investment funds managed by Pharmakon Advisors and Athyrium Capital Management.

BioPharma Provides $150MM Royalty-Backed Debt Financing to Halozyme

Halozyme Therapeutics entered into a $150 million royalty-back debt financing with BioPharma Credit Investments as collateral agent and lender and Athryrium Capital Management as lender.